Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Staszewski

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
JAMA|July 10, 1996
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working GroupC Katlama, D Ingrand, C Loveday, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 1, 1990
[Prospective study of primary and secondary prevention of Pneumocystis carinii pneumonia with pentamidine aerosol]S Staszewski, S Trinder, A Gottstein, et al.
AIDS (London, England)|August 16, 2001
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNAN Clumeck, F Goebel, W Rozenbaum, et al.
The Journal of Infectious Diseases|July 9, 1999
CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus loadV Miller, S Staszewski, C Sabin, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 1, 1990
[Comparison of the effect of 2 therapy concepts in the treatment of Pneumocystis carinii pneumonia. Cotrimoxazole for 21 days versus sequential therapy with cotrimoxazole followed by pentamidine inhalation]E B Helm, S Staszewski, K Arasteh, et al.
AIDS (London, England)|June 17, 1999
Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapyS Staszewski, V Miller, C Sabin, et al.
Atherosclerosis|February 6, 2007
Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosisM W Lorenz, C Stephan, A Harmjanz, et al.
The Journal of Infectious Diseases|August 7, 1999
A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapyM Hirsch, R Steigbigel, S Staszewski, et al.
AIDS (London, England)|November 4, 2000
The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral loadV Miller, C A Sabin, A N Phillips, et al.
AIDS (London, England)|March 9, 2000
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapyV Miller, M Ait-Khaled, C Stone, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
JAMA|July 10, 1996
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working GroupC Katlama, D Ingrand, C Loveday, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 1, 1990
[Prospective study of primary and secondary prevention of Pneumocystis carinii pneumonia with pentamidine aerosol]S Staszewski, S Trinder, A Gottstein, et al.
AIDS (London, England)|August 16, 2001
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNAN Clumeck, F Goebel, W Rozenbaum, et al.
The Journal of Infectious Diseases|July 9, 1999
CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus loadV Miller, S Staszewski, C Sabin, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 1, 1990
[Comparison of the effect of 2 therapy concepts in the treatment of Pneumocystis carinii pneumonia. Cotrimoxazole for 21 days versus sequential therapy with cotrimoxazole followed by pentamidine inhalation]E B Helm, S Staszewski, K Arasteh, et al.
AIDS (London, England)|June 17, 1999
Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapyS Staszewski, V Miller, C Sabin, et al.
Atherosclerosis|February 6, 2007
Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosisM W Lorenz, C Stephan, A Harmjanz, et al.
The Journal of Infectious Diseases|August 7, 1999
A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapyM Hirsch, R Steigbigel, S Staszewski, et al.
AIDS (London, England)|November 4, 2000
The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral loadV Miller, C A Sabin, A N Phillips, et al.
AIDS (London, England)|March 9, 2000
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapyV Miller, M Ait-Khaled, C Stone, et al.
Pageof 10